Deals In September BI, Inflammasome Ally In $160m Retinal Diseases Collaboration Boehringer Ingelheim International GmbH and Inflammasome Therapeutics Inc. agreed to co-develop up to three candida
Medtech mergers and acquisition activity hit its lowest point for the year in November with only six deals recorded on Medtech Insight's M&A Tracker – significantly lower than the previous months